[et_pb_section fb_built=”1″ admin_label=”News T-Hero Section” module_class=”hero tert” _builder_version=”4.18.0″ _module_preset=”default” background_image=”https:\/\/aafa.org\/wp-content\/uploads\/2022\/07\/AAFA-Website_Tertiary_News.jpg” background_position=”top_right” custom_padding=”1%||1%||true|false” global_module=”2297″ saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” background_enable_image=”off” background_size=”initial” background_position=”bottom_left” background_horizontal_offset=”0%” custom_margin=”||||false|false” custom_padding=”2%||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Nav Parent Title” module_class=”tert-parent” _builder_version=”4.20.4″ _module_preset=”default” header_2_font=”|600|||||||” header_2_text_align=”left” header_2_text_color=”#FFFFFF” header_2_font_size=”32px” custom_margin=”||0px||false|false” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_code admin_label=”Breadcrumbs” module_class=”bcrumb” _builder_version=”4.17.4″ _module_preset=”default” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”||||false|false” custom_css_main_element=”font-size:16px;||color: #fff;” global_colors_info=”{}”][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Main Content” _builder_version=”4.17.4″ _module_preset=”default” background_enable_image=”off” background_size=”initial” background_position=”bottom_right” custom_padding=”2%||2%||true|false” collapsed=”off” global_colors_info=”{}”][et_pb_row admin_label=”Title Row” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title author=”off” comments=”off” featured_image=”off” admin_label=”Blog Post Title” _builder_version=”4.18.0″ _module_preset=”default” title_level=”h2″ title_font=”|600|||||||” title_text_color=”#008C99″ title_font_size=”39px” meta_font=”|700|||||||” meta_text_color=”#505050″ meta_font_size=”20px” title_font_size_tablet=”30px” title_font_size_phone=”26px” title_font_size_last_edited=”on|phone” meta_font_size_tablet=”20px” meta_font_size_phone=”16px” meta_font_size_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_post_title][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Page Content” module_class=”secondary-intro” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ text_line_height=”1.5em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” custom_margin=”||3%||false|false” global_colors_info=”{}”]<\/p>\n
\u200bPatient advocacy group applauds efforts to make asthma medicine more affordable<\/em><\/p>\n Washington, D.C., March 8, 2024 \u2013 The Asthma and Allergy Foundation of America (AAFA) is leading advocacy efforts to change the drug pricing ecosystem and to make medicines more affordable and accessible for the 27 million people in the United States with asthma.<\/p>\n Boehringer Ingelheim announced<\/a> it will cap out-of-pocket costs of its COPD and asthma inhaler portfolio at $35 per month for patients who have commercial insurance or no insurance.<\/p>\n \u201cThe announced price cap from Boehringer Ingelheim is a step toward improving access to essential asthma medicine and demonstrates that the voice of the asthma patient community is being heard,\u201d states Kenneth Mendez, president and CEO of AAFA. \u201cAAFA will continue to advocate that all stakeholders in the drug pricing ecosystem take steps to improve affordability and access for life-saving medicines.\u201d<\/p>\n Last fall, AAFA shared patient stories and its Asthma Disparities in America report<\/a> with the Senate Health, Education, Labor, and Pensions (HELP) Committee which then launched an investigation into the high price of asthma inhalers<\/a> early this year.<\/p>\n In addition to pharmaceutical manufacturers, pharmacy benefit managers, insurance companies, employers, and federal policies all affect the final price paid for medicines. Unfortunately, these complex layers often mean that the current system discriminates against people who need these drugs the most.<\/p>\n Differences in prevalence and mortality rates present startling evidence of racial disparities in asthma. Black and Hispanic individuals have higher rates of asthma and are more likely to be uninsured or underinsured. Deaths due to asthma\u2014although decreasing overall\u2014occur at a much higher rate in the Black and Puerto Rican populations than in the White population. Black individuals are nearly three times as likely to die from asthma than White individuals.<\/p>\n AAFA\u2019s\u00a0research indicates that when the cost of medicine becomes a barrier to treatment<\/a>, people with asthma\u00a0resort to rationing or simply discontinue use.<\/a><\/p>\n Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex, and often leaves patients with few affordable options.<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Press Contact” _builder_version=”4.24.0″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” global_colors_info=”{}”]<\/p>\n Press Contact:<\/strong> [\/et_pb_text][et_pb_text admin_label=”About ” _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#F5EDDF” custom_padding=”4%|4%|4%|4%|true|true” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n
\n
Andy Spears
Asthma and Allergy Foundation of America (AAFA)
media@aafa.org<\/p>\n